We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
TODAY'S HIGH
1341
TODAY'S LOW
1327.65
52 WEEK HIGH
1918.75
52 WEEK LOW
1295.95
% of Shares Held by
All Insider
75.57%
% of Shares Held by
Institutions
11.11%
% of Float Held by
Institutions
45.47%
Number of Institutions
Holding Shares
45
MARKET CAP
22602.94 Cr.
ETERPRISE VALUE
21397.43 Cr.
NO. OF SHARES
16.94 Cr.
BOOK VALUE
85.901
DIV. YIELD
60%
DEBT
23.24 Cr.
GROSS PROFIT
1899.81 Cr.
CASH
1305.23 Cr.
REVENUE
3287.51 Cr.
REVENUE/SHARE
194.087
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | -1812.38 Cr. | 225 Cr. | 92 Cr. | 20 Cr. |
| Change To Liabilities | 102.37 Cr. | 107.40 Cr. | -48.22 Cr. | -100.04 Cr. |
| Total cashflows from Investing Activities | -405.50 Cr. | 418.59 Cr. | -56.84 Cr. | -153.45 Cr. |
| Net Borrowings | -15.61 Cr. | -14.98 Cr. | -15.05 Cr. | -40.60 Lakhs |
| Total Cash from Financing Activities | -524.24 Cr. | -696.13 Cr. | -427.62 Cr. | -358.35 Cr. |
| Other Liabilities | -4.72 Cr. | 85.07 Cr. | 160.06 Cr. | 55.26 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 1694.72 Cr. | 358.14 Cr. | 93.20 Cr. | 445.39 Cr. |
| Change in Cash | -119 Cr. | 300.37 Cr. | 6.03 Cr. | -102.32 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 810.74 Cr. | 577.92 Cr. | 490.49 Cr. | 409.48 Cr. |
| Depreciation | 68.19 Cr. | 70.25 Cr. | 72.89 Cr. | 38.83 Cr. |
| Other Cashflows from Investing Activities | 1408 Cr. | 55.30 Cr. | 3.55 Cr. | 69.78 Cr. |
| Dividends Paid | -506.64 Cr. | -677.62 Cr. | -338.81 Cr. | -296.46 Cr. |
| Change to Inventory | 12 Cr. | -46.79 Cr. | -67.71 Cr. | 13.68 Cr. |
| Change to Account Receivables | 10.20 Cr. | -99.93 Cr. | -4.97 Lakhs | 26.89 Cr. |
| Other Cashflows from Financing Activities | -1.99 Cr. | -3.53 Cr. | -73.75 Cr. | -61.49 Cr. |
| Change to Net Income | -1072.02 Cr. | 94.73 Cr. | 270.54 Cr. | -80.30 Cr. |
| Capital Expenditures | -34.64 Cr. | -44.22 Cr. | -155.89 Cr. | -291.28 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 779.05 Cr. | 550.49 Cr. | 305.75 Cr. | 682.66 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 693.69 Cr. | 616.10 Cr. | 586.93 Cr. | 557.06 Cr. |
| Selling General Administrative | 610.23 Cr. | 747.05 Cr. | 774.14 Cr. | 692.54 Cr. |
| Gross Profit | 1921.84 Cr. | 1864.66 Cr. | 1899.37 Cr. | 1749.27 Cr. |
| Ebit | 693.69 Cr. | 616.10 Cr. | 586.93 Cr. | 557.06 Cr. |
| Operating Income | 693.69 Cr. | 616.10 Cr. | 586.93 Cr. | 557.06 Cr. |
| Other Operating Expenses | 549.73 Cr. | 422.40 Cr. | 455.98 Cr. | 451.64 Cr. |
| Interest Expense | -2 Cr. | -3.53 Cr. | -6.33 Cr. | -55.43 Lakhs |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 398.28 Cr. | 192.35 Cr. | 212.54 Cr. | 237.27 Cr. |
| Total Revenue | 3278.03 Cr. | 3198.86 Cr. | 3224.38 Cr. | 3128.11 Cr. |
| Total Operating Expenses | 2584.34 Cr. | 2582.75 Cr. | 2637.44 Cr. | 2571.05 Cr. |
| Cost of Revenue | 1356.19 Cr. | 1334.19 Cr. | 1325 Cr. | 1378.84 Cr. |
| Total Other Income Expense Net | 85.36 Cr. | -65.60 Cr. | -281.18 Cr. | 125.60 Cr. |
| Discontinued Operations | 1313.95 Cr. | 1313.95 Cr. | 1313.95 Cr. | 1313.95 Cr. |
| Net Income from Continuous Ops. | 380.77 Cr. | 358.14 Cr. | 93.20 Cr. | 445.39 Cr. |
| Net Income Applicable to Common Shares | 1694.72 Cr. | 358.14 Cr. | 93.20 Cr. | 445.39 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 34.50 Cr. | 43.36 Cr. | 49.62 Cr. | 65.54 Cr. |
| Capital Surplus | 0 | 0 | 0 | 0 |
| Total Liabilities | 1970.32 Cr. | 1614.28 Cr. | 1312.62 Cr. | 1771.48 Cr. |
| Stock Holder Equity | 2662.96 Cr. | 1499.07 Cr. | 1820.60 Cr. | 2139.82 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 1115.43 Cr. | 647.04 Cr. | 496.61 Cr. | 904.03 Cr. |
| Total Assets | 4633.28 Cr. | 3113.36 Cr. | 3133.23 Cr. | 3911.31 Cr. |
| Common Stock | 169.41 Cr. | 169.40 Cr. | 169.40 Cr. | 169.40 Cr. |
| Retained Earnings | 0 | 1334.54 Cr. | 1654.02 Cr. | 1969.27 Cr. |
| Other Liabilities | 264.27 Cr. | 261.55 Cr. | 263.81 Cr. | 316.98 Cr. |
| Good Will | 0 | 0 | 0 | 0 |
| Treasury Stock | 2493.55 Cr. | -4.87 Cr. | -2.82 Cr. | 1.15 Cr. |
| Other Assets | 565.30 Cr. | 513.21 Cr. | 481.64 Cr. | 469.15 Cr. |
| Cash | 2484.51 Cr. | 405.18 Cr. | 104.81 Cr. | 98.77 Cr. |
| Current Liabilities | 1698.43 Cr. | 1332.47 Cr. | 1021.95 Cr. | 1454.31 Cr. |
| Long Term Asset Charges | 113.15 Cr. | 103.12 Cr. | 110.48 Cr. | 62.22 Cr. |
| Short Long Term Debt | 0 | 2.40 Lakhs | 15.30 Lakhs | 40.60 Lakhs |
| Other Stockholder Equity | 2493.55 Cr. | -4.87 Cr. | -2.82 Cr. | 1.15 Cr. |
| Property Plant Equipment | 325.44 Cr. | 354.12 Cr. | 827.08 Cr. | 1367.09 Cr. |
| Total Cur. Assets | 3708.04 Cr. | 2202.65 Cr. | 1774.88 Cr. | 2009.46 Cr. |
| Long Term Investments | 0 | 0 | 0 | 5.50 Lakhs |
| Net Tangible Assets | 2628.46 Cr. | 1455.71 Cr. | 1770.97 Cr. | 2074.28 Cr. |
| Short Term Investments | 365.59 Cr. | 732.01 Cr. | 957.01 Cr. | 1049.01 Cr. |
| Net Receivables | 205.24 Cr. | 241 Cr. | 130.41 Cr. | 210 Cr. |
| Long Term Debt | 0 | 0 | 2.40 Lakhs | 17.70 Lakhs |
| Inventory | 534.70 Cr. | 546.69 Cr. | 483.03 Cr. | 486.49 Cr. |
| Accounts Payable | 570.55 Cr. | 464.47 Cr. | 357.06 Cr. | 405.81 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account